Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CTOR

Citius Oncology Inc

Feb 13 • 04:00PM ET

1.22

+0.04 3.39 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Feb 13, 11:15 AMCitius Oncology (CTOR) reports fiscal Q4 2025 results with non-GAAP EPS of -$0.38 (-322% YoY) and revenue of $3.9M, missing revenue estimates, with sales driven by the initial LYMPHIR launch that marks its transition to a commercial-stage company.

Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.31	Insider Own	81.22%	Shs Outstand	84.80M	Perf Week	7.96%
Market Cap	107.70M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	16.58M	Perf Month	10.91%
Enterprise Value	104.20M	PEG	-	EPS next Q	-	Inst Own	10.17%	Short Float	7.32%	Perf Quarter	-8.96%
Income	-23.64M	P/S	27.34	EPS this Y	-	Inst Trans	0.85%	Short Ratio	2.64	Perf Half Y	-29.07%
Sales	3.94M	P/B	1.77	EPS next Y	-	ROA	-23.58%	Short Interest	1.21M	Perf YTD	22.00%
Book/sh	0.69	P/C	14.75	EPS next 5Y	-	ROE	-47.41%	52W High	6.19 -80.29%	Perf Year	-4.69%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	- -309.67%	ROIC	-37.99%	52W Low	0.55 121.58%	Perf 3Y	-88.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	79.99%	Volatility	8.56% 8.04%	Perf 5Y	-
Dividend TTM	-	EV/Sales	26.45	EPS Y/Y TTM	-77.52%	Oper. Margin	-567.43%	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.32	Sales Y/Y TTM	-	Profit Margin	-599.28%	RSI (14)	60.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.83	EPS Q/Q	32.01%	SMA20	9.42%	Beta	2.97	Target Price	6.00
Payout	-	Debt/Eq	0.07	Sales Q/Q	-	SMA50	8.51%	Rel Volume	0.47	Prev Close	1.18
Employees	-	LT Debt/Eq	0.07	Earnings	Feb 13 BMO	SMA200	-24.31%	Avg Volume	459.95K	Price	1.22
IPO	Dec 08, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	216,816	Change	3.39%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-25	Upgrade	Maxim Group	Hold → Buy	$6
Nov-27-24	Initiated	Maxim Group	Buy	$3

Feb-13-26 08:00AM	Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
08:00AM	Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
Feb-12-26 06:55AM	Citius Oncology and Uniphar sign European distribution deal for Lymphir (Pharmaceutical Business Review)
Feb-11-26 08:00AM	Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar (PR Newswire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
04:30PM	Loading…
Dec-23-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire) -9.84%
Dec-10-25 04:30PM	Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Dec-09-25 08:30AM	Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) +6.42%
Dec-04-25 08:37AM	Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim (PR Newswire) -9.02%
Dec-01-25 12:00PM	Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) (PR Newswire) +19.71%
Nov-25-25 08:00AM	Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting (PR Newswire) +8.04%
Nov-21-25 08:37AM	Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration (PR Newswire)
Oct-21-25 08:19AM	Citius Oncology finalises McKesson deal for Lymphir distribution (Pharmaceutical Business Review)
Oct-20-25 08:37AM	Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR Commercial Launch (PR Newswire) +5.29%
Oct-17-25 05:00PM	Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences (PR Newswire) -5.03%
08:47AM	Loading…
Oct-16-25 08:47AM	Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR (PR Newswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-07-25 08:47AM	Citius Oncology Establishes International Access to LYMPHIR via Named Patient Programs in Southern Europe (PR Newswire)
Sep-10-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Sep-09-25 08:30AM	Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Aug-22-25 08:47AM	Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch (PR Newswire) +7.36%
Aug-12-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire) +5.92%
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire) +5.52%
Jul-17-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire)
Jul-16-25 09:15AM	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire)
Jul-15-25 08:32AM	Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora (PR Newswire) -20.62%
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire) +26.81%
Jun-17-25 08:08AM	Citius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 (PR Newswire)
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
08:37AM	Loading…
Jun-09-25 08:37AM	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire) +17.13%
May-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Feb-14-25 04:30PM	Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -5.60%
Feb-06-25 08:55AM	Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services (PR Newswire) -5.56%
Jan-07-25 08:08AM	Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 (PR Newswire) -11.69%
07:57AM	Citius Oncology to explore strategic alternatives (TipRanks)
Jan-06-25 07:50AM	Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives (PR Newswire) +18.46%
Dec-31-24 07:10AM	Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital (TipRanks)
Dec-27-24 05:00PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire) +8.33% +7.69%
05:00PM	Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +6.30%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) +8.38% -5.60%
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTOR

Citius Oncology Inc

Upgrade your FINVIZ experience